Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF JANUARY 06, 2018 FBO #5888
DOCUMENT

Q -- AMA Oncotype DX Test - Attachment

Notice Date

1/4/2018
 

Notice Type

Attachment
 

NAICS

621511 — Medical Laboratories
 

Contracting Office

00504;Department of Veterans Affairs;Contracting Section;7201 I-40 West Suite 100;Amarillo TX 79106
 

ZIP Code

79106
 

Solicitation Number

36C25718Q0323
 

Response Due

1/12/2018
 

Archive Date

3/13/2018
 

Point of Contact

Lula Hill
 

Small Business Set-Aside

N/A
 

Description

The Amarillo VA Health Care System (AVAHCS) is seeking Service Disabled Veteran Owned Small Business (SDVOSB), Veteran Owned Small Business (VOSB) or Small Business (SB) sources capable of meeting the requirement listed below. The acquisition will be accomplished using commercial item procedures in accordance with FAR Part 13. NOTE: TO QUALIFY SDVOSB AND VOSB VENDORS MUST BE CERTIFIED IN THE VA VENDOR INFORMATION PAGES (VIP) DATABASE. The North American Industry Classification System (NAICS) are 621511. Any SDVOSB, VOSB or SB firms who wish to identify their interests and capability to provide this service must notify the Contract Specialist no later than NOON PM Central Time, January 12, 2018. Notification shall be e-mailed to Lula Hill, at lula.hill3@va.gov. Provide Cage Code and or DUNS number. DISCLAIMER This Source Sought Notice is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this Notice that is marked as proprietary will be handled accordingly. In accordance with the Federal Acquisition Regulation, responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this Notice. SCOPE: PERFORMANCE WORK STATEMENT Amarillo VA Health Care System, Pathology and Laboratory Medicine Services For Oncotype DX testing The Amarillo VA Health Care System (VAHCS) and Pathology and Laboratory Medicine Service (P&LMS) located in Amarillo, Texas, requests a Vendor to perform services in the area of gene expression assay and Oncotype DX testing for cancers of the breast, colon, and prostate. This specialized testing is beyond our scope of services to provide in-house. BACKGROUND: The use of the Oncotype DX test is a recommendation by the National Comprehensive Cancer Network (NCCN) that is followed by our former VISN 18 Hematologists and Oncologists counter parts. These tests aid in determining the next step to take in the treatment and prognosis of patients diagnosed with early stage I or stage II, node negative, estrogen-positive invasive breast cancer, colon cancer, and prostate cancer. The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a patient s tumor in order to optimize cancer treatment decisions. By providing answers to key questions about the aggressiveness of and appropriate treatment for early-stage cancer, our practice-changing tests help physicians and patients select the right treatment at the right time in each individual case. In this way, Oncotype DX testing helps patients and their physicians to optimize their cancer care and outcomes, enabling many patients to avoid unnecessary procedures and therapies, and saving the healthcare system billions of dollars in unnecessary costs. BILLING Vendor shall bill monthly in arrears and process the billing through the Government E-Invoice system. www.Tungsten-network.com VENDOR RESPONSIBILITIES The vendor shall provide all personnel, equipment, tools, materials, supervision, other items and non-personal services necessary to perform gene expression assay, Oncotype DX testing as defined in the Performance Work Statement. The Vendor shall perform to the standards in this contract. The Vendor shall provide AVAHCS services for: Oncotype DX testing- Breast (CPT code 81519) Oncotype DX testing- Colon (CPT code 81525) Oncotype DX testing-Prostate (CPT code 81479) The Vendor shall develop and maintain an effective quality control program to ensure services are performed in accordance with this PWS. The Vendors quality control program is the means by which he assures himself that his work complies with the requirement of this contract. The Vendor shall develop and implement procedures to identify, prevent and ensure non-recurrence of defective services. The Vendor shall agree to participate in an on-going Quality Assurance surveillance plan. The Vendor shall be evaluated by the Government under this contract in accordance with the Quality Assurance Surveillance Plan. This plan is primary focused on what the Government must do to ensure that the Vendor had performed in accordance with the performance standards. It defines how the performance standards will be applied, the frequency of surveillance, and the minimum acceptable defect rate(s). Vendor shall provide specimen transportation kit boxes and all applicable forms necessary to perform the specific testing. AVHCS shall provide the information as requested on the Oncotype DX Assay Requisition Form. The Vendor shall send the patients results to the lab department listed on the Requisition Form via fax (1-806-354-7865). The Vendor provides reports that summarize the findings of the patient s test. A detailed Oncotype DX assay report is generated for each patient, with assay results provided as a Recurrence Score result (0-100). The Vendor s report includes Clinical Experience for women with node-negative, ER-positive breast cancer and post-menopausal women with node-positive, hormone receptor positive breast cancer and all other results available to the commercial market place to the AVAHCS P&LMS. ACCREDITATION: The Vendor shall provide all licenses, permits, be able to meet accreditation and certificates required by law. The laboratory must be accredited by the College of American Pathologist (CAP) or be able to meet the Joint Commission and Clinical Laboratory Improvement Amendments (CLIA) (Public law 100-578) certifications. The Contractor will provide current copies of these records at the time of contract award and annually on the anniversary date of contract award to the COTR or, upon request. CONFDENTIALLTY/SECURITY The Contractor, Contractor employees, and Subcontractors shall be subject to the Privacy Act of 1974 and HIPAA of 1996. The contractor is not authorized to release any medical record information. The VAMC is the sole entity authorized to release this information upon written request submitted via facsimile or mail from the patient. The VAMC will provide the Contractor with access to pertinent patient medical information, within the existing privacy rules and regulations, for the purpose of providing coordinated comprehensive medical care. Contractors shall ensure the confidentiality of all patient information and shall be held liable in the event of the breach of confidentiality. The C and A requirements do not apply; a Security Accreditation Package is not required.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/VA/VAAHCS/VAAHCS/36C25718Q0323/listing.html)
 

Document(s)

Attachment
 

File Name: 36C25718Q0323 36C25718Q0323_1.docx (https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=4000119&FileName=36C25718Q0323-000.docx)

Link: https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=4000119&FileName=36C25718Q0323-000.docx

 

Note: If links are broken, refer to Point of Contact above or contact the FBO Help Desk at 877-472-3779.
 

Place of Performance

Address: Department of Veterans Affairs;6010 Amarillo Blvd W;Amarillo, TX

Zip Code: 79106
 

Record

SN04781090-W 20180106/180104230651-144db03a6ab91dc18215942b384a7aa1 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |